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Background: MUC16 (CA125) is a large transmembrane mucin protein (> 200 kDa) aberrantly expressed in
approximately 80% of human epithelial ovarian cancers (EOC). MUC16 expression in EOC cells is associated with
increased tumorigenesis and inhibiton of genotoxic drug-induced apoptosis. However, the mechanism by which
MUC16 mediates these effects is unknown. In the present study, we investigated the mechanisms by which MUC16
attenuates TRAIL-induced apoptosis.
Methods: MUC16 expression was down-regulated by stably expressing an anti-MUC16 single-chain antibody (scFv)
targeted to the endoplasmic reticulum (ER), which prevents cell surface localization of MUC16 in OVCAR3 cells. We
also generated a MUC16 C-terminal domain (MUC16CTD) construct that was stably expressed in MUC16 negative
SKOV3 cells.
Results: We show that MUC16 attenuates apoptosis, activation of caspase-8 and mitochondria activation in
EOC cells in response to TRAIL. MUC16 decreases TRAIL receptor R2 (DR5) expression and inhibits pro-caspase-8
activation at the death-inducing signaling complex (DISC). MUC16CTD expression is sufficient to attenuate the
TRAIL signaling cascade. MUC16 knockdown decreases caspase-8 inhibitor cFLIP mRNA levels, increases cFLIP
degradation, and consequently increases TRAIL-induced apoptosis. Down-regulation of cFLIP following treatment
of MUC16-expressing OVCAR3 cells with cFLIP siRNA also increases TRAIL-induced apoptosis.
Conclusions: These findings indicate that MUC16 protects EOC cells against TRAIL-induced apoptosis through
multiple mechanisms including the blockade of TRAIL R2 expression and the regulation of cFLIP expression at
both the transcriptional and the protein level.
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Apoptosis plays a critical role in cellular homeostasis
and prevents the development of tumor cells. The apop-
totic response of cells can be induced by the intrinsic
and the extrinsic pathway, the former being mediated by
the mitochondria and the latter activated by ligand
stimulation of death receptors at the cell surface [1].
Death receptor ligands such as tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) trigger rapid
apoptosis in vitro and in vivo in various tumor cell types* Correspondence: alain.piche@usherbrooke.ca
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unless otherwise stated.[2-7]. TRAIL binds to death receptors, TRAIL-R1 (DR4)
and -R2 (DR5), whose cytoplasmic death domain (DD)
signals downstream caspase activation to mediate TRAIL-
induced apoptosis [8]. In contrast, TRAIL-R3, TRAIL-R4
and osteoprotegerin (OPG) act as decoy receptors [9-11].
Upon receptor activation, FADD and pro-caspase-8 are
recruited to form a death-inducing signaling complex
(DISC) [12]. When recruited to the DISC, pro-caspase-8
becomes activated and subsequently activates downstream
effectors caspases-3, -6 and -7, leading to apoptosis. Pro-
caspase-8 activation can directly result in cleavage of
caspase-3 to execute apoptosis (type I cells) or cleave Bid
to produce a truncated form (tBid), which induces the
release of cytochrome c from the mitochondria leading totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cells) as it is the case for EOC cells. The cellular FLICE
inhibitory protein (cFLIP) regulates both recruitment and
processing of pro-caspase-8 within the DISC [13]. There
are two major splice variants expressed in human cells,
cFLIPS (25 kDa) and cFLIPL (55 kDa) [14]. Both isoforms
are able to block, although via different mechanisms,
caspase-8 activation within the DISC. Consequently, cFLIP
isoforms are potent negative regulators of the TRAIL
signaling cascade.
MUC16 mucin (CA125) is a large transmembrane glyco-
protein that shares many characteristics of the membrane-
bound mucin proteins [15-18]. Whereas MUC16 expression
is found in the majority of EOC of serous type, it is not de-
tected in normal ovarian epithelium [19]. The structure of
MUC16 consists of an enormous N-terminal domain with
more than 22,000 heavily glycosylated amino acid resi-
dues, a central domain containing up to 60 glycosylated
repeat sequences constituting the characteristic tandem
repeats of mucins and a C-terminal domain (CTD)
[15-18]. The MUC16CTD anchors the protein at the cell
surface and consists of a 229 amino acid extracellular
region containing a potential proteolytic cleavage site, a 23
residue transmembrane domain, and a 31 amino acid
cytoplasmic tail. MUC16 extracellular domain binds to
mesothelin [20-22], galectin-3 [23] and Siglec-9 [24].
MUC16 may be involved in suppressing natural killer cell
activity [25]. Expression of MUC16CTD in malignant cells
enhances migration, invasion, tumor growth and metasta-
sis whereas MUC16 knockdown completely abolishes
tumor formation in vitro and in vivo [26]. MUC16 knock-
down sensitizes ovarian cancer cells to apoptosis induced
by genotoxic drugs [27]. The mechanisms by which the
CTD of MUC16 mediates these biological effects are
unknown.
In the present study, we show that MUC16 decreases
TRAIL-R2 expression, increases cFLIP expression, blocks
recruitment of caspase-8 to the DISC, and consequently




The OVCAR3 and SKOV3 human ovarian cancer cell
lines were obtained from the American Type Culture
Collection (Manassas, VA). OVCAR3 cells were grown
in RPMI 1640 (Wisent, St-Bruno, QC, Canada) supple-
mented with 20% heat-inactivated FBS (Wisent), 2 mM
L-glutamine (Wisent), 100 units/ml penicillin, 100 μg/ml
streptomycin and 10 μg/ml insulin, and maintained at
37°C in a humidified 5% CO2 incubator. The SKOV3 cell
line was maintained in DMEM/F12 (Wisent) supple-
mented with 10% heat-inactivated FBS, glutamine andanti-
biotics. OVCAR3 R350 cells are a TRAIL-resistantisogenic cell line that was obtained by exposing OVCAR3
cells to stepwise increases of TRAIL over 4 months. This
cell line has been described previously [28]. The construc-
tion of the anti-MUC16 scFv has been previously described
in detail [26,27]. Two independent stable OVCAR3 clones
expressing the anti-MUC16 scFv (1:9#7 scFv, 1:9#9 scFv),
and the control scFv (ctrl scFv) were generated by transfec-
tion of these plasmids into OVCAR3 cells and their valid-
ation has been described previously [26,27]. Derivation of
MUC16CTD-expressing SKOV3 cells has also been previ-
ously described [26,27]. In this construct, MUC16CTD is
tagged at the C-terminal with an His and a c-myc tag to
allow easy detection of MUC16CTD expression.
Reagents
Recombinant human TRAIL was purchased from Pepro-
Tech, inc. (Rocky Hill, NJ). The TRAIL-R2 agonist anti-
body (clone 71903), the tetrapeptide caspase inhibitor,
z-IETD-fmk, anti-XIAP and anti-caspase-8 antibodies
were obtained from R&D Systems (Minneapolis, MN).
Anti-caspase-9, anti-caspase-3, anti-Bid, and anti-Bcl-XL,
anti-mouse HRP and anti-rabbit HRP antibodies were
purchased from Cell Signaling (Beverly, MA). TRAIL-
Flag and anti-TRAIL-R1 to R4 receptor antibodies used
for flow cytometry were from Alexis Biochemicals
(San Diego, CA). Anti-FADD and anti-TRAIL R2 used
to perform Western blotting were from EMD Millipore
(Etobicoke, ON, Canada). Anti-c-FLIPL and anti-c-FLIPS
antibodies were purchased from Calbiochem (LaJolla,
CA). Anti-Bcl-2 and anti-CA125 M11 antibodies were
obtained from Dako (Burlington, ON, Canada) and anti-
CA125 OC125 antibody was from Zymed (South San
Francisco, CA). XTT, phenazine methosulfate, propidium
iodide, cycloheximide, anti-Flag M2 and anti-tubulin were
from Sigma (Oakville, ON, Canada). Anti-Bax and anti-
myc-789 used for immunoprecipitation experiments were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Anti-myc 9E10 antibody used for Western blot detection,
real-time PCR Taqman Gene Expression Assay Master
Mix, Flip primers for RT-PCR assays and Flip siRNA were
from Life Technologies Inc (Burlington, ON, Canada).
Anti-His antibody used for immunoprecipitation experi-
ments was from Bioshop Canada (Burlington, ON).
RNAse was obtained from Roche (Laval, QC, Canada).
Cytotoxicity assays
Cell viability was determined by the XTT assay. Briefly,
cells were plated at 20,000 cells/well in 96-well plates.
The next day, cells (confluence 60-70%) were treated
with human recombinant TRAIL or anti-TRAIL-R2
agonist antibody as indicated and incubated for 48 h. In
some experiments, synthetic caspase inhibitor (25 μM
z-IETD-fmk) was added 1 h before the addition of 25
ng/ml of TRAIL. At the termination of the experiment,
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fresh media (without phenol red) containing phenazine
methosulfate and XTT was added for 30 min. The absorb-
ance of each well was determined using a microplate
reader at 450 nm (TecanSunrise, Research Triangle Pack,
NC). The percentage of cell survival was defined as the
relative absorbance of treated versus untreated cells. All
assays were performed in triplicate and repeated three
times.
Apoptosis assays
Caspase-3 fluorogenic protease assay was performed
according the manufacturer’s protocol (R&D Systems,
Minneapolis, MN). In brief, 3 × 106 cells were lysed in
250 μl of cell lysis buffer, and total cell lysates were
incubated with 50 μM of DEVD-AFC substrate for 1 h.
Caspase-3 activity was measured on a Versa Fluor fluore-
meter (BioRad, Hercules, CA). Protein concentration of
the lysates was measured with Bio-Rad protein assay kit
according to the manufacturer’s recommendations.
To determine the sub-G0 DNA content, floating and
adherent cells were harvested, washed with PBS/2% FBS
and fixed with cold ethanol for 2 h. Cell pellets were
resuspended, washed with PBS, filtered on nylon mesh
membrane (40 μm mesh) to remove cell aggregates.
Cells were then incubated with propidium iodide (final
concentration 20 μg/ml in PBS, RNase A (0.5 mg/ml)
and 0.1% Triton X100 overnight at 4°C. Cells were ana-
lysed on a FACSCAN flow cytometer (Becton Dickinson,
Mississauga, ON).
The release of nucleosomal DNA into the cytoplasm
as a measure of apoptosis was determined using the Cell
Death Detection ELISA kit according to the manufac-
turer’s instructions (Roche, Laval, QC, Canada). Briefly,
cells were lysed and the extracted cytoplasmic nucleo-
somal DNA was captured in ELISA wells containing
anti-histone antibodies. The nucleosomal DNA was de-
tected with an anti-DNA-POD conjugated antibody. The
absorbance of each well was determined using a micro-
plate reader at 410 nm (TecanSunrise, Research Triangle
Pack, NC). Each sample was assayed in duplicate. Data
are from three independent experiments.
The mitochondrial membrane integrity in OVCAR3
controls and knockdown cells was assayed using the
MitoLight™ Apoptosis Detection Kit (EMD Millipore).
Cells were cultured in Labtek II chamber slides (Nalge
Nunc International, Naperville, IL) in RPMI1640 supple-
mented with 20% FBS at 37°C to achieve 70-80% conflu-
ence. Fresh media containing 200 ng/ml (OVCAR3
cells) or 500 ng/ml (SKOV3 cells) TRAIL was then
added and cells were incubated at 37°C in 5% CO2 for
45-60 min. After treatment with TRAIL, unfixed cells
were incubated with the MitoLight™ reagent (Chemicon,
Billerica, CA) (dilution 1:1,500) for 20 min at 37°C. Thewells were washed and identical fluorescein and rhoda-
mine fields were digitized at 400× magnification using
an Olympus X170 fluorescence microscope. Dye uptake
by non-apoptotic mitochondria concentrates in the
mitochondrial membrane and is visualized as the accu-
mulation of red fluorescence in the organelles. However,
apoptotic mitochondria are incapable of accumulating
the dye due to loss of membrane potential and therefore
the monomeric dye in the cytoplasm appears green.
Immunoprecipitation and immunoblot analysis
Whole cell extracts were prepared in lysing buffer
containing protease inhibitors and were separated by
12% SDS-PAGE gels. Proteins were transferred to PVDF
membranes (Roche, Laval, Québec, Canada) by electro-
blotting, and immunoblot analysis was performed as
previously described (18). All primary antibodies were
incubated overnight at 4°C in 5% milk. Proteins were
visualized by enhanced chemiluminescence (GE Health-
care, Baie d’Urfé, Québec, Canada). SKOV3 empty vec-
tor and SKOV3 MUC16CTD cell lines were lysed for an
hour on ice and immunoprecipitates were obtained
using anti-HIS, anti-myc-789 or isotypic anti-mouse IgG
monoclonal antibodies conjugated to protein-G agarose
(EMD Millipore, Billerica, CA). Immune complexes were
separated by SDS-PAGE, immunoblotted and probed
with anti-c-myc 9E10 antibodies and visualized by
enhanced chemiluminescence. For TRAIL DISC analy-
sis, 80% confluent cells were stimulated with 1 μg/ml
(OVCAR3) or 2 μg/ml (SKOV3) of Flag-tagged TRAIL
and 3 μg/ml of anti-Flag M2 (pre-incubated for 15 min)
in RPMI medium for 30 or 60 min. Cells were then
washed with ice-cold PBS and lysed with lysis buffer
containing 30 mM Tris-Hcl, 150 mM NaCl, 1% Triton
supplemented with protease inhibitors. Lysates were
cleared, normalized for protein concentration and the
DISC were immunoprecipitated with protein G agarose
beads overnight at 4°C on a rotating rod. For Western
blot analysis, the beads were washed 4 times with lysis
buffer and heated in lysis buffer 4×SDS before the super-
natants were separated by 12% SDS-PAGE. NIH Image J
software was used to quantify the intensity of each band
on Western blots. In some experiments, cycloheximide
(200 μM) in DMSO was added for the indicated time.
RT-PCR analysis
Total RNAs were extracted from Ctrl scFv- and MUC16
scFv-expressing OVCAR3 cells using Trizol (Life Tech-
nologies) according to the manufacturer’s recommenda-
tions. RNA integrity was verified on gel by ethidium
bromide staining and quantification was performed by
determining absorbance at 260 nm. For each sample,
total RNA (2 μg) and 1 μM of oligo dT (Promega) were
incubated for 5 min at 70°C followed by the addition of
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Madison, WI) and 2.5 μM dNTP for 1 h at 42°C. Ampli-
fication of cDNA was done in a PCR reaction using the
Taqman Gene Expression Assay Master mix from Ap-
plied Biosystems as follow: 2 min at 50°C, 10 min at
95°C and then 40 cycles of 15 s at 94°C and 1 min at
60°C on a StepOne Plus real time PCR system (Life
Technologies Inc). The primers for the amplification of
cFLIPL (Gene expression assay Hs00153439_m1) and
cFLIPS (Gene expression assay Hs00354474_m1) were
from Life Technologies Inc.Flow cytometry for TRAIL receptors and MUC16 expression
Cell monolayers were detached using EDTA, washed
with PBS and fixed with paraformadehyde 4% in PBS for
20 min. Cells were incubated with the following un-
labeled primary antibodies (10 μg/ml) for 1 h at room
temperature with human anti-TRAIL-R1, -R2, -R3, and
-R4 antibodies. The isotypic control antibody was a
normal mouse IgG (BD Biosciences, Mississauga, ON).
After three washes with PBS, cells were incubated with
PE-conjugated donkey anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA) for 45 min at room
temperature. Cells were washed three times and analyzed
immediately using a FACSCAN flow cytometer (Beckton
Dickinson). After they had reached 80-90% confluence,
MUC16 knockdown cells and ctrl scFv cells as well as the
parental OVCAR3 cells were fixed with 4% paraformalde-
hyde. Cell surface MUC16 tumor antigen was detected by
flow cytometry using the anti-CA125 M11 mouse mono-
clonal antibody and revealed using an anti-mouse PE-
conjugated (Jackson ImmunoResarch).Immunofluorescence
Stable OVCAR3 clones expressing the various scFvs
were grown on glass slides until a 50-70% confluence
was reached. Glass slides were then washed in cold PBS
and cells fixed in ice-cold methanol for 10 min at -20°C.
Glass slides were next rinsed 5 min in cold PBS, perme-
abilized in PBS containing 0.1% Triton X-100 for 5 min
on ice and rinsed again in PBS. Slides were blocked in
PBS/2% BSA on ice for 45 min and incubated with pri-
mary antibodies in blocking buffer at room temperature
for 1 h. Slides were washed 3 times in cold PBS, incu-
bated for 30 min at room temperature with anti-mouse
secondary antibodies coupled to Texas Red (1:1000;
Molecular Probes, Eugene, OR), washed with PBS and
mounted for visualization by fluorescence microscopy.
Expression of MUC16 was detected using M11 antibody
(1:500). Nuclear staining performed with DAPI (100
ng/ml) (Roche), was viewed and photographed using an
Olympus X170 fluorescence microscope.Statistical analysis
Statistical comparisons between two groups were per-
formed using the Student’s t-test and with ANOVA
when comparing the data with more than two treat-
ments groups. Statistical significance was indicated by
P < 0.05.
Results
MUC16 attenuates TRAIL-induced apoptosis and pro-
caspase-8 activation
To determine whether MUC16 affects TRAIL signaling,
we knockdown MUC16 cell surface expression. The
cell surface localization of MUC16 was confirmed by
co-localization with membrane protein Caveolin1
(Additional file 1: Figure S1). We thus derived anti-
MUC16 single-chain antibodies (scFvs), containing an
ER retention signal, and a control scFv (Ctrl scFv), which
does not bind to MUC16 [26,27]. These constructs were
stably expressed in MUC16-expressing OVCAR3 cells
and two independent MUC16 scFv-expressing cell lines
were derived (1:9#7 scFv and 1:9#9 scFv) as previously
described [26,27]. As compared to the control scFv,
expression of MUC16 scFvs strongly decreased MUC16
expression at the cell surface in OVCAR3 cells as dem-
onstrated by both immunofluorescence and immunoblot
(Figure 1). Treatment of control and MUC16 scFv-
expressing OVCAR3 cells with increasing concentrations
(0 to 100 ng/ml) of TRAIL induced dose-dependent cell
death (Figure 2A). However, MUC16 knockdown cells
were significantly more sensitive to TRAIL-induced cell
death. As shown in Figure 2B, following treatment with
TRAIL (10 ng/ml), MUC16 knockdown cells were
rounded and floated in the medium indicating cell death
whereas the control scFv-expressing cells formed a typ-
ical healthy epithelioid monolayer. To further confirm
that MUC16 knockdown enhances TRAIL-induced cell
death, Ctrl scFv- and 1:9#7 scFv-expressing OVCAR3
cells were incubated with an anti-TRAIL-R2 agonist
antibody. As shown in Figure 2C, anti-TRAIL-R2
agonist-induced cell death was enhanced in MUC16
knockdown cells. Apoptosis, as measured by % of hypo-
diploid cells assessed by flow cytometry, was similar for
all cell populations in the absence of TRAIL (Figure 2D)
suggesting that MUC16 knockdown by itself does not
induce apoptosis. However, MUC16 knockdown signifi-
cantly sensitized OVCAR3 cells to TRAIL-induced
apoptosis (P < 0,001) (Figure 2D). In concert with these
findings, down-regulation of MUC16 increased TRAIL-
induced caspase-8 activation as demonstrated by the
near complete disappearance of pro-caspase-8 and the
appearance of p18 actives fragments after 3 h when
compared to control scFv-expressing cells (Figure 2E).
Analysis of TRAIL signaling cascade also indicated that
cleaved mature forms of caspase-9 (p35) and caspase-3



























Figure 1 Cell surface knockdown of MUC16 in OVCAR3 sublines expressing ER-targeted anti-MUC16 scFvs. Ctrl scFv-expressing cell
line and MUC16 knockdown (1:9#7 scFv and 1:9#9 scFv) cell were assessed for MUC16 expression by immufluorescence with anti-CA125 M11
antibody. (A) The expression of MUC16 in non-permeabilized cells was determined by immunofluorescence. Cells were incubated with the
anti-CA125 M11 antibody and nuclei were stained with DAPI. (B) Immunoblot analysis of MUC16 expression. Equal loading was confirmed using
an anti-tubulin antibody.
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1 h. In contrast, control scFv-expressing cells displayed a
more limited caspase-9 and caspase-3 activation over
time in the presence of TRAIL under the same condi-
tions. Caspase activation in control cells was seen only
after 3 or 4 h and cleaved active caspase-8 (p18) and
caspase-3 (p17) were not observed even after 4 h. The
generation of active caspase-3 fragments in MUC16 knock-
down OVCAR3 cells was confirmed by measuring the
cleavage of fluorogenic caspase-3 substrates (Additional file
1: Figure S2A). Pre-incubation of cells with caspase-8 in-
hibitor z-IETD-fmk prior to TRAIL treatment (25 ng/ml)
had little effect on TRAIL-induced apoptosis in the
control scFv-expressing cells but significantly improved the
survival of MUC16 knockdown cells (Additional file 1:
Figure S2B).
Caspase-8 mediates the cleavage of full length Bid to
generate a truncated form (tBid) which translocates to
the mitochondria to promote the insertion of Bax into
the outer membrane mitochondrial membrane [29,30].
tBid is therefore a key component that links the death
receptor pathway to mitochondria-mediated effector
caspase activation in type II cells. We thus assessed the
impact of MUC16 knockdown on Bid cleavage in
OVCAR3 cells. We observed the near complete dis-
appearance of full length Bid within 3 h in MUC16
knockdown cells treated with TRAIL (Figure 2F). In con-
trast, the disappearance of Bid occurred only after 8 h in
control scFv-expressing cells. The cleavage of Bid in
MUC16 knockdown cells was almost completely inhib-
ited by pre-incubation with caspase-8 inhibitor z-IETD-
fmk (Additional file 1: Figure S2C). To evaluate whether
MUC16 also attenuates TRAIL-induced mitochondrial
activation, mitochondria membrane integrity was assessed
by the uptake of a lipophilic cationic dye. In the absence
of TRAIL, there were little or no visible apoptotic mito-
chondria in both knockdown and control cells as indicatedby the absence of green-labelled cells (Figure 2G). The red
fluorescence represents dimeric dye that has accumulated
in the intact mitochondria membrane. However, com-
pared to control scFv-expressing cells, MUC16 knock-
down cells treated with TRAIL displayed substantially
more apoptotic mitochondria as shown by a greater num-
ber of green-labeled cells indicating the accumulation of
dye in the cytoplasm due to the inability of mitochondria
to concentrate the dye within their membranes related to
a loss of membrane potential. All together, these results
indicate that MUC16 attenuates TRAIL-induced apop-
tosis, activation of caspase-8 and mitochondrial activation.
To further support the role of MUC16 in TRAIL re-
sistance, we examined the expression of MUC16 in nine
ovarian cancer cell lines. As shown in Table 1, with the
exception of SKOV3 and OVC116 cell lines, the expres-
sion of MUC16 correlated with TRAIL sensitivity. More
interestingly, MUC16 expression in TRAIL resistant
OVCAR3 cells (OVCAR3 R350) was significantly higher
than its isogenic sensitive parental cells (Figure 2G). The
generation of the OVCAR3 R350 cell line has been
previously described by our group [28].
MUC16 C-terminal domain (CTD) is sufficient to attenuate
TRAIL-induced apoptosis and signaling
To determine whether the MUC16CTD is sufficient to
attenuate TRAIL-induced apoptosis, the MUC16 nega-
tive SKOV3 cell line was transfected to stably express an
empty vector (SKOV3-EV) or MUC16CTD as previously
described [26,27]. MUC16CTD expression was detect-
able in SKOV3-MUC16CTD cells but not in control
SKOV3-EV cells (Figure 3A). The appropriate cell sur-
face localization of MUC16CTD in these cells has been
validated previously [27]. Because we have previously
shown that SKOV3 cells are less sensitive to TRAIL than
OVCAR3 cells [7], higher doses of TRAIL were used for
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Figure 2 (See legend on next page.)
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Figure 2 MUC16 knockdown enhances TRAIL-induced activation of caspase-8 and apoptosis. (A) Cells were incubated for 48 h with
increasing concentrations of TRAIL. Cell viability was measured by the XTT assay. All assays were performed in triplicate and repeated three times.
Data are expressed as the mean of pooled data from all three experiments: bars, ± SEM. (B) Cells were incubated in the presence or absence
of TRAIL (100 ng/ml) for 24 h, and morphological changes were assessed by phase contrast microscopy. Representative fields from one of two
independent experiments are shown. (C) Cells were treated with anti-TRAIL-R2 agonist for 48 h. Cell viability was measured by the XTT assay.
All assays were performed in triplicate and repeated three times. Data are expressed as the mean of pooled data from all three experiments:
bars, ± SEM. (D) Cells were treated with TRAIL (100 ng/ml) for 24 h and stained with PI, and the subG0/G1 DNA content was analyzed by flow
cytometry. Results from two independent experiments are shown. (E) Cells were treated with TRAIL (100 ng/ml) for up to 8 h and cell lysates
were analyzed by immunoblots. (F) Cells were incubated with TRAIL for the indicated times and cell lysates were immunoblotted with anti-Bid
antibody. The anti-Bid antibody used does not detect the truncated form of Bid. (G) Cells were cultured for 24 h without TRAIL and the
mitochondrial membrane integrity was assessed using MitoLight™. In treated cells, fresh culture medium containing 200 ng/ml of TRAIL was
added for 45 min prior to MitoLight™ staining. Cells containing red-labeled mitochondria are scored as viable cells. (H) OVCAR3 and isogenic
TRAIL resistant R350 cells were treated with TRAIL (100 ng/ml) for 48 h and cell viability was assessed by XTT. Immunoblot showing expression
of MUC16 in the upper panel.
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creased in SKOV3 cells expressing MUC16CTD com-
pared to empty vector (EV)-expressing cells (P < 0.001).
TRAIL-induced apoptosis was decreased by about 50%
in MUC16CTD-expressing SKOV3 cells compared to
control SKOV3-EV cells (Figure 3D).
In SKOV3-EV cells, TRAIL induced the cleavage of
pro-caspase-8 into the active p43/41 after about 1 h
(Figure 3E). Because these cells are less sensitive to TRAIL
than OVCAR3 cells, the mature active p18 fragments were
not detected in SKOV3-EV cells even after 6 h. The cleavage
of caspase-3 and caspase-9 was evident after 2 h as deter-
mined by the disappearance of pro-caspase form (Figure 3E).
The expression of MUC16CTD markedly decreased the
TRAIL-induced processing of caspase-8, caspase-3 and
caspase-9 in SKOV3 cells. There was no evidence of pro-
caspase cleavage in these cells even after 6 h (Figure 3E). To
determine whether TRAIL-induced activation of the mito-
chondrial pathway was attenuated by MUC16CTD, mito-
chondria membrane integrity was assessed by the uptake
of a lipophilic cationic dye. Experiments showed that
MUC16CTD strongly decreased the number of apoptotic
mitochondria (Figure 3D). All together, these findings
indicate that MUC16CTD is sufficient to inhibit TRAIL-







OVCAR3 R350 1250 > 500
SKOV3 < 10 > 500
CaOV3 49,6 20
OVC116 < 10 25
OVC118 325 125
COV2 628 > 500
COV17 842 > 500MUC16 decreases TRAIL-R2 expression and its recruitment
at the DISC
Differential sensitivity to TRAIL-induced apoptosis in
tumor cells has been previously attributed to differential
expression of death and decoy receptors [30]. Indeed,
the levels of TRAIL receptors (TRAIL-R1 and -R2) are
closely related to apoptosis induced by TRAIL. It is
therefore possible that MUC16 regulates the TRAIL
signaling cascade by altering the expression of TRAIL
receptors. In this context, we examined the cell surface
expression of the four TRAIL receptors by flow cytome-
try in control and MUC16 knockdown cells. TRAIL-R2
expression was significantly increased in MUC16 knock-
down OVCAR3 cells whereas the expression of the other
TRAIL receptors remained unchanged (Figure 4A). In
concert with these results, the assessment of TRAIL-R2
by immunoblot showed increased expression of TRAIL-
R2 in MUC16 knockdown cells (Figure 4B). In contrast,
the expression of MUC16CTD was sufficient to decrease
TRAIL-R2 expression in SKOV3 cells (Figure 4C).
Binding of TRAIL to TRAIL-R1/TRAIL-R2 results in
recruitment of FADD to the DISC and, in turn, FADD
recruits pro-caspase-8 [8]. Because MUC16 decreases
TRAIL-R2 expression, we determine whether MUC16
affects DISC formation. The composition of TRAIL
DISC was analyzed by immunoprecipitation and im-
munoblotting using cross-linked recombinant Flag-
tagged soluble TRAIL. In MUC16 knockdown OVCAR3
cells, pro-caspase-8 activation at the DISC, as demon-
strated by the presence of p43/41 fragments, was clearly
enhanced when compared to the control scFv-expres-
sing cells (Figure 4D). Immunoblot analysis further re-
vealed increased TRAIL-R2 recruitment at the DISC in
MUC16 knockdown cells (Figure 4D) which is consistent
with the increased expression of TRAIL-R2 in these cells
(Figure 4A and B). In line with experiments in OVCAR3
cells and those shown in Figure 4C, fewer TRAIL-R2
receptors were pulled down by immunoprecipitating



















































































































Figure 3 MUC16CTD is sufficient to attenuate TRAIL-induced apoptosis and caspase-8 activation in SKOV3 cells. (A) Lysates from SKOV3-
EV or SKOV3-MUC16CTD were immunoprecipitated with anti-His or anti-c-myc-789 antibodies and subjected to immunoblotting with anti-c-myc 9E10
antibody. (B) SKOV3 cells expressing MUC16CTD or the empty vector (EV) were treated for 48 h with increasing concentrations of TRAIL. Cell viability
was measured by the XTT assay and the percentage of cell viability was defined as the relative absorbance of treated versus untreated cells. All assays
were performed in triplicate and repeated three times, and data are expressed as the mean of triplicate samples: bars, ± SEM. (C) Morphological analysis
under phase contrast microscopy of SKOV3 cells treated with TRAIL (500 ng/ml) was also performed. Representative fields of one of three independent
experiments are shown. (D) SKOV3-EV or SKOV3-MUC16CTD cells were incubated in the presence or absence of 500 ng/ml TRAIL and apoptosis was
assessed by flow cytometry by analyzing the subG0/G1 DNA content. The percentage of apoptotic cells is indicated. Results from two independent
experiments are shown. (E) SKOV3-EV and SKOV3-MUC16CTD cells were treated with TRAIL (500 ng/ml) for up to 6 h and cell lysates were analyzed by
immunoblots using anti-caspase-8, anti-caspase-3 and anti-caspase-9 antibodies. The pro-caspase forms and their cleavage products are indicated by
the arrows to the left of the panels. (F) Fluorescence microscopic analysis of the mitochondrial membrane permeability in SKOV3 cells. SKOV3-EV and
SKOV3-MUC16CTD cells were cultured for 24 h without TRAIL and the mitochondrial membrane integrity was assessed using the MitoLight™. In treated
cells, fresh culture medium containing 500 ng/ml of TRAIL was added for 60 min prior to MitoLight™ staining.
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http://www.biomedcentral.com/1471-2407/14/234cleaved caspase-8 fragments (p43/41) were detected only
in the DISC of control SKOV3-EV cells after 60 min
(Figure 4E). These data suggest that MUC16 attenuates
TRAIL-induced apoptosis by decreasing TRAIL-R2 ex-
pression and consequently decreasing its recruitment at
the DISC.MUC16 regulates cFLIP expression
The cellular FLICE inhibitory protein (cFLIP) regulates
both recruitment and processing of pro-caspase-8 within
the DISC [13,14]. Although several cFLIP isoforms have
been described, the two main isoforms expressed in hu-








































































































































Figure 4 MUC16 decreases TRAIL-R2 expression and blocks caspase-8 activation at the DISC. (A) Monolayers of Ctrl scFv- and MUC16
scFv-expressing cells were detached using EDTA, washed with PBS and fixed with paraformadehyde 4% in PBS. Cells (non-permeabilized) were
incubated with anti-TRAIL receptors R1, R2, R3 and R4 antibodies. Expression of TRAIL receptors was determined by flow cytometry and expressed
as median fluorescence units. Results are from three independent experiments. (B) Lysates from Ctrl scFv- and MUC16 scFv-expressing OVCAR3
cells were immunoblotted with TRAIL-R2 antibody. (C) Lysates from empty vector (EV)- and MUC16CTD-expressing SKOV3 cells were immuno-
blotted with TRAIL-R2 antibody. (D) Ctrl scFv- and MUC16 scFv-expressing OVCAR3 cells were incubated with FLAG-tagged TRAIL (1 μg/ml) for
various times and the DISC was immunoprecipitated with anti-FLAG antibody. The membrane was immunoblotted with anti-caspase-8 antibody
or with anti-TRAIL R2. Data are representative of at least two independent experiments. (E) Empty vector (EV)- and MUC16CTD-expressing SKOV3
cells were incubated with FLAG-tagged TRAIL (2 μg/ml) and the DISC was immunoprecipitated with anti-FLAG antibody. The membrane was
immunoblotted with anti-caspase-8 antibody or with anti-TRAIL R2. Data are representative of at least two independent experiments.
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tors of the TRAIL signaling cascade, we first assessed
whether MUC16 affects the transcription of cFLIPL and
cFLIPS. We thus examined cFLIPL and cFLIPS mRNA
levels in control and MUC16 scFv-expressing OVCAR3
cells. cFLIPL and cFLIPS mRNA levels, as determined by
quantitative real time PCR, were significantly decreasedin MUC16 knockdown OVCAR3 cells compared to
control scFv expressing cells (Figure 5A). In concert with
these findings, the expression of both cFLIPL and cFLIPS
were decreased in MUC16 knockdown cells when
assessed by immunoblot (Figure 5B). To determine if
MUC16 affects cFLIPL stability, we blocked de novo pro-




























































































































































































Figure 5 MUC16 increases cFLIP expression to attenuate TRAIL-induced apoptosis. (A) Real-time PCR analysis of cFLIPS and cFLIPL transcript
levels in Ctrl scFv and MUC16 scFv-expressing OVCAR3 cells. Results were standardized using primers of the housekeeping gene RPLPO. Data are
expressed as fold change relative to levels observed in Ctrl scFv-expression OVCAR3 cells. Data are from two independent experiments. (B) Lysates
from Ctrl scFv- and MUC16 scFv-expressing OVCAR3 cells were immunoblotted with cFLIPL and cFLIPS antibodies. (C) OVCAR3 Ctrl scFv and
OVCAR3 MUC16 1:9#7 and 1:9#9 scFv were incubated with cycloheximide (100 μM). Lysate were obtained at different time points and immuno-
blot analysis was performed with anti-cFLIPL antibody. Intensity of cFLIPL signal was determined by densitometric scanning and plotted as the
percentage of cFLIPL remaining compared with the control (0 h). (D) OVCAR3 Ctrl scFv and OVCAR3 MUC16 1:9#7 scFv were incubated with
FLAG-tagged TRAIL (1 μg/ml) and the DISC was immunoprecipitated with anti-FLAG M2 antibody. The membrane was immunoblotted with
anti-cFLIPL and with anti-cFLIPs antibodies. (E) OVCAR3 cells were transfected with control nontargeting siRNA (NT siRNA) or cFLIP siRNA pools
and then incubated with TRAIL. Immunoblot analysis (24 h) was performed with anti-cFLIPL and anti-cFLIPS antibodies and showed decreased
cFLIPL and cFLIPS expression in cFLIP siRNA-transfected cells. Apoptosis was qualitatively assessed by phase contrast microscopy in TRAIL treated
cells (100 ng/ml; 6 h) and showed morphological changes suggestive of apoptotic cells in cFLIP siRNA-transfected cells. Representative fields
from one of two independent experiments are shown. Apoptosis was also by ELISA as described in Methods and expressed as fold increased rela-
tive to control (untreated) cells with the mean of triplicates from three independent experiments ± SD. (F) Lysates from empty vector- and
MUC16 CTD-expressing SKOV3 cells were immunoblotted with cFLIPL and cFLIPS antibodies.
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addition of cycloheximide. Densitometric scanning of
the signals showed that the estimated half-lives ofcFLIPL in control scFv- and MUC16 scFv-expressing
OVCAR3 cells are > 3 and ≤ 0.5 hours, respectively
(Figure 5C). The half-live of cFLIPS was estimated to
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(data not shown). Because of the very low expression of
cFLIPS in MUC16 knockdown cells, its half-live could
not be determined using this approach. Nonetheless,
these data indicate that MUC16 stabilizes cFLIPL which
might contribute to attenuate TRAIL-induced apoptosis
in MUC16 expressing malignant cells. Indeed, cFLIPL
and cFLIPS recruitment at the DISC were both de-
creased in MUC16 knockdown cells as compared to
control scFv-expressing cells (Figure 5D). In addition,
silencing cFLIP in OVCAR3 cells was associated with
increased apoptosis in response to TRAIL (Figure 5E).
Consistent with these findings, the expression of MUC
16CTD in SKOV3 cells was associated with the up-
regulation of cFLIPL and cFLIPS as demonstrated by im-
munoblot (Figure 5F). Of note, the expression of other
key regulators of the TRAIL signaling cascade such as
Bcl-2, Bcl-XL, Bax, FADD and XIAP were unaffected by
MUC16 (Additional file 1: Figures S2D and S2E). These
data indicate that MUC16 transcriptionally increases
both isoforms of cFLIP and at least cFLIPL protein,
thereby increasing their recruitment at the DISC to
attenuate TRAIL-induced apoptosis.
Discussion
MUC16 is a mucin protein overexpressed by most
human ovarian epithelial cancers [19,31,32]. Moreover, a
correlation exists between rising and falling levels of
serum MUC16 and clinical progression and regression
of the disease [31]. In this context, it is considered to be
one of the most useful clinical markers for ovarian
cancer. Although its biological functions remain largely
unknown, MUC16 expression in EOC cells has been
associated with a more aggressive phenotype [26]. In
addition, our group has recently implicated MUC16 in
the regulation of genotoxic drug-induced apoptosis but
the mechanisms associated with the effect were unclear
[27]. In the present study, we demonstrate that MUC16
is involved in the regulation the death receptor pathway.
Cell surface MUC16 knockdown, mediated by anti-
MUC16 scFvs, sensitizes ovarian cancer cell line OVCA
R3 to apoptosis in response to TRAIL, a member of the
TNF family of cytokines that represents a promising
candidate for cancer treatment because of its ability
to selectively induce apoptosis in malignant cells [5].
TRAIL-induced activation of initiator caspase-8 and ef-
fector caspase-3 was enhanced in MUC16 knockdown
cells. MUC16 knockdown was associated with increased
TRAIL-R2 expression and recruitment at the DISC.
MUC16 knockdown also decreases the expression of the
caspase-8 inhibitor cFLIP at the transcriptional level and
enhanced the protein degradation of cFLIPL isoform,
thereby enhancing apoptosis in response to TRAIL.
Conversely, MUC16CTD expression attenuated TRAIL-induced apoptosis and caspase activation by decreasing
TRAIL-R2 expression and recruitment at the DISC and
by increasing cFLIP expression. These data suggest that
MUC16 plays an important role in regulating the death
receptor signaling cascade.
Mucins play a role in carcinogenesis by promoting
anchorage-independent growth and tumorigenicity of
human epithelial cells. Altered expression of mucins has
been associated with increased invasiveness, enhanced
tumor cell growth and metastasis, and modulation of
cell adhesion in carcinomas [32-38]. Based on its simi-
larity of structure with mucins, it is conceivable that
MUC16 exerts a number of functions that parallel those
of other mucins. Interestingly, it has been reported that
MUC1 can block death receptor-mediated apoptosis in
breast and colonic carcinoma cells [39,40]. This effect
has been attributed to localization of MUC1 C-terminal
domain to the mitochondria which attenuated mito-
chondrial activation [40] or to the ability of MUC1 to
directly bind caspase-8 and FADD, thereby inhibiting
recruitment of caspase-8 at the DISC [39]. Thus, similar
to MUC1, MUC16 attenuates TRAIL-induced apoptosis
in EOC cells and both mucins may act upstream of the
mitochondria. However, the mechanisms by which they
inhibit TRAIL signaling differ. MUC16 acts through
multiple mechanisms to attenuate TRAIL-induced apop-
tosis. MUC16 down-regulates TRAIL-R2 and up-regulates
cFLIP expression both resulting in the inhibition of
caspase-8 activation at the DISC. The basis for this dis-
crepancy in term of mechanisms between MUC1 and
MUC16 is unclear but may relate to the fact that different
cellular models were used or, more likely, to the fact that
MUC1 and MUC16 share very little sequence homology
in their cytoplasmic tail [41]. MUC16 has a very short
intracellular domain (31 a.a.) compared to MUC1 (72 a.a.).
Nonetheless, collectively the data suggest that transmem-
brane mucins, such as MUC1 and MUC16, regulate the
extrinsic pathway of apoptosis. By doing so, mucins may
enable tumor cells to escape the cytotoxic effect of im-
mune cells and promote tumor development.
Our study provides important insight into the molecu-
lar mechanisms by which MUC16 regulates TRAIL-
mediated apoptosis. TRAIL binds to distinct receptors
but among these receptors, only TRAIL-R1 and TRAIL-
R2 contain cytoplasmic death domains that can trans-
duce an apoptotic signal upon TRAIL binding. Our
studies show that although both TRAIL-R1 and TRAIL-
R2 are expressed at the surface of OVCAR3 and SKOV3
cell populations, TRAIL-R2 appears to be the main re-
ceptors used by TRAIL to transduce a death signal in
these cells. This is supported by the observation MUC16
knockdown enhances anti-TRAIL-R2 agonist-mediated
apoptosis. Although the precise mechanism by which
MUC16 alters TRAIL-R2 expression selectively remains
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a lower expression of TRAIL-R2. Lack or low expression
of TRAIL-R2 has been previously associated with TRAIL
resistance [30]. Reduced TRAIL-R2 expression on the
cell surface may result from either a lower level of
expression in the cell or failure to deliver the receptor to
the cell surface. Western blotting showed that the total
protein levels of TRAIL-R2 are significantly lower in
MUC16 expressing cells. This observation does not sug-
gest a defective transport or a trafficking problem as we
would expect identical levels of TRAIL-R2 in MUC16-
expressing and control cells. A more likely explanation
would be a regulation of TRAIL-R2 at the transcrip-
tional levels or increased protein degradation. Micro-
array analysis to investigate the global changes in
MUC16 knockdown OVCAR3 cells revealed a signifi-
cant (2.71) up-regulation of TRAIL-R2 gene but not
TRAIL-R1 (unpublished data). We are currently investi-
gating the mechanisms by which MUC16 regulates
TRAIL-R2 expression. Markedly increased pro-caspase-
8 cleavage was seen within the DISC of MUC16 knock-
down OVCAR3 cells while pro-caspase-8 activation into
the DISC was not detected in the SKOV3 ectopically ex-
pressing MUC16CTD. Furthermore, OVCAR3 cells en-
dogenously expressing high levels of MUC16 displayed
very little pro-caspase-8 processing after incubation with
TRAIL for 1 h (Figure 4D). After initial cleavage of pro-
caspase-8 at the DISC, active caspase-8 may directly
activate effector caspases such as caspase-3 or may alter-
natively activate the cleavage and translocation of the
pro-apoptotic protein Bid to the mitochondria [42]. The
activation of the mitochondrial apoptotic pathway leads
to cytochrome c release, caspase-9 and caspase-3 activa-
tion [42]. Kinetic analysis of caspase-9 and caspase-3
activation in OVCAR3 showed that the mitochondrial
pathway is activated regardless of the cell’s MUC16 sta-
tus. However the activation of this pathway is markedly
enhanced in MUC16 knockdown cells (Figure 3E). Inter-
estingly, addition of a caspase-9 inhibitor abrogated this
effect indicating that mitochondrial amplification of
TRAIL death signaling is important in MUC16 knock-
down cells (data not shown). Based on our results, we
propose that MUC16 interferes with the caspase-8 acti-
vation at the DISC and consequently affects initiation
of the mitochondrial amplification loop that leads to
TRAIL-induced apoptosis.
It was recently shown that MUC16 silencing in breast
cancer cells is associated with up-regulation of TRAIL-
R1 (DR4) and pro-apoptotic molecules Bid and Bax, and
down-regulation of Bcl-2 [43]. The authors speculated
that these changes might promote TRAIL-induced
apoptosis in breast cancer cells but the level of the
blockade in the death receptor signaling cascade was
not established. In EOC cells, neither the expression ofMUC16CTD nor MUC16 knockdown was associated
with altered expression of Bid, Bax, Bcl-2 or TRAIL-R1,
and the blockade occurred upstream of the mitochon-
dria. The basis for the discrepancy between these results
is not clear. The role of anti-apoptotic proteins such as
Bcl-2 and Bcl-XL in protecting from drug-induced apop-
tosis has been shown to be cell context dependent [44].
Conclusions
In summary, our results indicated that MUC16 attenuates
TRAIL-induced apoptosis in EOC cells. Further, MUC16
down-regulates TRAIL R2 expression and recruitment at
the DISC. MUC16 also increase the expression of both
cFLIPL and cFLIPS. Altogether, these effects contribute
to the MUC16-mediated attenuation of TRAIL-induced
apoptosis. The present findings may also have therapeutic
implications. In this context, a combination of TRAIL
with small molecules that block cell surface localization or
the function of the intracellular domain of MUC16 might
prove more effective in killing TRAIL resistant ovarian
cancer cells. A clearer understanding of the mechanisms
underlying MUC16 intracellular signaling could lead to
the development of novel approaches to enhance the
efficacy of TRAIL for the treatment of ovarian cancer.
Additional file
Additional file 1: Figure S1. Expression and localization of MUC16 in
OVCAR3 cells. Immunofluorescence studies were performed as described in
Methods. MUC16 and caveolin1 were visualized with Texas Red (MUC16) or
Alexa fluorescent label (green; caveolin1). Representative images are shown.
Scale = 100 μM. Data demonstrate that MUC16 co-localization at the cell
membrane with caveolin1. Figure S2. MUC16 enhanced TRAIL-induced Bid
cleavage and mitochondrial activation. (a) The parental OVCAR3 cell line
and sublines (ctrl scFv, 1:9#7 scFv and 1:9#9 scFv) were treated with TRAIL
(100 ng/ml) and caspase-3 activity was measured using a caspase-3 fluoro-
genic protease assay. In brief, after TRAIL treatment, cells were lysed in
250 μl of lysis buffer and lysates were incubated with 50 μM of DEVD-AFC
substrate for 1 h. Caspase-3 activity was measured using the Versa Fluor
fluorometer (b) Parental NIH:OVCAR3 cells and sublines (ctrl scFv, 1.9#7 and
1.9#9) were treated with TRAIL (100 ng/ml) for 6 h. The activity of caspase-3
was measured using a caspase-3 fluorogenic protease assay with 50 μM of
DEVD-AFC as a substrate. Results are expressed as relative fluorescence unit
(RFU) of caspase-3 activity normalized for the total amount of protein in the
extract and represent mean ± SEM (n = 3). *, indicates P < 0.001.
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